APAS Study: Pragmatic Evaluation of the Performance and Safety of the Anchorsure System® Transvaginal Device for Surgical Treatment of Apical Prolapse in Women. A Post-market Multicentre Prospective Observational Cohort Study.

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

Pelvic Organ Prolapse affects 50% of parous women, and apical prolapse is one of the most common types of prolapse. Treatment for apical prolapse ranges from observation, non-surgical treatment or surgical repair. An anchoring device can reduce dissection and operative time and is meant to provide strong fixation whilst minimizing potential postoperative pain by avoiding neurovascular injuries. These potential advantages must be evaluated in terms of performance and safety. This cohort study will be on patients undergoing sacrospinous fixation with the Anchorsure® system with a follow-up of 36 months.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 50
View:

• Women with pelvic organ prolapse with leading edge at or beyond the hymen as confirmed by the pelvic organ prolapse quantification system (POP-Q), i.e. Ba ≥ -1 cm for the anterior compartment, and/or Bp ≥ -1 cm for the posterior compartment, and/or C ≥ -1 cm for the apical compartment including recurrence.

• Women due for POP surgery using the Anchorsure System® for apical prolapse suspension with or without concomitant native tissue repair, with or without concomitant hysterectomy and with or without concomitant sling for stress urinary incontinence.

• All women who have not indicated any objection to participating in the study.

• All women who have been correctly informed.

Locations
Other Locations
France
La Rochelle General Hospital
RECRUITING
La Rochelle
Lille University Hospital
RECRUITING
Lille
Kremlin-Bicêtre Hospital
RECRUITING
Paris
Clinique Sainte-Anne
RECRUITING
Strasbourg
Contact Information
Primary
Renaud de TAYRAC, Professor
renaud.detayrac@chu-nimes.fr
+334 66 68 32 16
Backup
Anissa MEGZARI
drc@chu-nimes.fr
+334 66 68 42 36
Time Frame
Start Date: 2023-05-11
Estimated Completion Date: 2028-06-01
Participants
Target number of participants: 120
Related Therapeutic Areas
Sponsors
Collaborators: Centre Hospitalier de La Rochelle, Clinique Sainte-Anne, Strasbourg, Kremlin-Bicetre Hospital, Paris, University Hospital, Lille
Leads: Centre Hospitalier Universitaire de Nīmes

This content was sourced from clinicaltrials.gov